Medical Analysis Services Tenders & Contracts

County Durham and Darlington NHS Foundation Trust (CDDFT) are seeking to appoint a single supplier to provide Teleradiology Reporting Services. The Trust operates across two large acute sites and several non-acute sites, serving the population of County Durham and Darlington. At County Durham and Darlington NHS Foundation Trust, our vision is to deliver care which is right first time, every time. We are guided by our core values of respect and dignity, compassion, quality care, improving lives, everyone counts and working together for patients. By placing people and communities at the heart of all that we do, we strive to create a supportive and inclusive environment for both patients and our workforce, ensuring that every individual receives safe, compassionate and joined-up care. Reporting requirements will include but are not limited to: MRI, CT, Plain Film, Nuclear Medicine, with limited reporting requiring Specialist Radiologists. The Trust are seeking a supplier who is able to provide reporting services twenty-four hours a day, seven days a week for Urgent and Emergency Radiology Reporting, as well as provide Elective Reporting. There is no volume commitment as part of this contract and the demand from the Trust may vary overtime dependent on in house reporting capacity. However, the supplier would hold an exclusive contract for the out of hours provision to maintain continuity on the basis that the supplier can meet the turnaround time outlined by the Trust. However, for all other reporting, the Trust will be able to use alternative suppliers if desired. As demand fluctuates, the supplier must be able to adapt to high and low demands for reporting services. Bidding suppliers will be evaluated in line with the below Provider Selection Regime (PSR) Key Criteria regulated scoring: 1: Quality and Innovation: 20% 2: Improving Access, Reducing Health Inequalities and Facilitating Choice: 15% 3: Integration, Collaboration and Service Sustainability: 15% 4: Value - Price: 40% 5: Social Value: 10%

County Durham and Darlington NHS Foundation Trust (CDDFT) are seeking to appoint a single supplier to provide Teleradiology Reporting Services. The Trust operates across two large acute sites and several non-acute sites, serving the population of County Durham and Darlington. At County Durham and Darlington NHS Foundation Trust, our vision is to deliver care which is right first time, every time. We are guided by our core values of respect and dignity, compassion, quality care, improving lives, everyone counts and working together for patients. By placing people and communities at the heart of all that we do, we strive to create a supportive and inclusive environment for both patients and our workforce, ensuring that every individual receives safe, compassionate and joined-up care. Reporting requirements will include but are not limited to: MRI, CT, Plain Film, Nuclear Medicine, with limited reporting requiring Specialist Radiologists. The Trust are seeking a supplier who is able to provide reporting services twenty-four hours a day, seven days a week for Urgent and Emergency Radiology Reporting, as well as provide Elective Reporting. There is no volume commitment as part of this contract and the demand from the Trust may vary overtime dependent on in house reporting capacity. However, the supplier would hold an exclusive contract for the out of hours provision to maintain continuity on the basis that the supplier can meet the turnaround time outlined by the Trust. However, for all other reporting, the Trust will be able to use alternative suppliers if desired. As demand fluctuates, the supplier must be able to adapt to high and low demands for reporting services. Bidding suppliers will be evaluated in line with the below Provider Selection Regime (PSR) Key Criteria regulated scoring: 1: Quality and Innovation: 20% 2: Improving Access, Reducing Health Inequalities and Facilitating Choice: 15% 3: Integration, Collaboration and Service Sustainability: 15% 4: Value - Price: 40% 5: Social Value: 10%

East Kent Hospitals University NHS Foundation Trust, supported by 2gether Support Solutions Limited, commenced a Most Suitable Provider Process under the Health Care Services (Provider Selection Regime) Regulations 2023 for the provision of outsourced radiology reporting services with operational business intelligence tool access.The proposed service included routine, urgent and out-of-hours radiology reporting, subspecialist reporting across relevant imaging modalities, and access to operational business intelligence functionality.Following completion of its assessment and subsequent review of its future service requirements, the Trust has decided not to award a contract through the Most Suitable Provider Process. The provider selection process has therefore been abandoned.The Trust intends to undertake a separate Competitive Process under the Health Care Services (Provider Selection Regime) Regulations 2023. Any future opportunity will be advertised separately through the applicable transparency notice and procurement documentation.

The Medicines and Healthcare products Regulatory Agency is the regulator of medicines, medical devices and blood components for transfusion in the UK. MHRA carries out a wide range of activities to fulfil its role as a patient safety regulator. This includes carrying out assessments of the safety, quality and efficacy of medicines, assessing the safety of proposed clinical trials of medicines and medical devices, inspecting the premises of those manufacturing, supplying or distributing medicines and monitoring the ongoing safety of all medical products, taking swift action where necessary to prevent harm to patients. The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products. The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment. With a wide range of critical deliverables, MHRA is seeking opportunities to add to its traditional in-house expertise through the establishment of additional sources of both capacity and capability. These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK. MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework. Such assessments may relate to marketing authorisation applications, clinical trial applications and a variety of other compliance activities. Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services. To achieve this ambition, MHRA wishes to establish a framework of specialist providers, which cover 3 Lots. Up to four suppliers, who meet the minimum criteria, may be awarded a place on each Lot. Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document). Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document). Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).

The Medicines and Healthcare products Regulatory Agency is the regulator of medicines, medical devices and blood components for transfusion in the UK. MHRA carries out a wide range of activities to fulfil its role as a patient safety regulator. This includes carrying out assessments of the safety, quality and efficacy of medicines, assessing the safety of proposed clinical trials of medicines and medical devices, inspecting the premises of those manufacturing, supplying or distributing medicines and monitoring the ongoing safety of all medical products, taking swift action where necessary to prevent harm to patients. The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products. The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment. With a wide range of critical deliverables, MHRA is seeking opportunities to add to its traditional in-house expertise through the establishment of additional sources of both capacity and capability. These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK. MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework. Such assessments may relate to marketing authorisation applications, clinical trial applications and a variety of other compliance activities. Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services. To achieve this ambition, MHRA wishes to establish a framework of specialist providers, which cover 3 Lots. Up to four suppliers, who meet the minimum criteria, may be awarded a place on each Lot. Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document). Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document). Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).